Animol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary Pharmaceuticals
Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing. The investment was led by Novalis Lifesciences, with participation from Finistere Ventures and existing investor Anterra Capital. The proceeds allow the company to expand and advance its pipeline of novel active pharmaceutical ingredients through clinical development and further enhance its cutting-edge drug discovery platform.
The $40Bn animal health industry continues to demand novel medicines to treat infectious and chronic diseases in companion and production animals. Recent successes, such as Apoquel™ from Zoetis and Nexguard™ from Boehringer Ingelheim, demonstrate the potential to build towards blockbuster franchises in the sector with novel pharmaceutical products.
“Pet parents and livestock farmers continue to demand novel veterinary pharmaceuticals that can protect animals against diseases and improve quality of life,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “Despite this strong demand, innovation is lagging. At Animol, we seek to address this innovation gap by leveraging the most advanced tools from human pharma to bring forward a wealth of new medicines that can benefit animals and the people who care for them.”
Founded in 2020 and incubated by Anterra Capital, Animol is pioneering the use of DNA Encoded Library (DEL) drug discovery technology coupled with powerful machine learning approaches to enable the rapid discovery of novel veterinary medicines.
“We have built Animol on the same cutting edge discovery techniques that we are using to disrupt drug discovery in human pharma (ZebiAI - acquired by Relay Therapeutics) and crop protection (Enko Chem),” said Philip Austin, Managing Partner at Anterra Capital. “Translating these tools to the massive opportunity available in veterinary pharma was the next obvious step and we are already seeing their use successfully build into a rich pipeline of promising compounds.”
Animol also announced that Marijn Dekkers PhD, founder & chairman of Novalis LifeSciences LLC will join the Board of Directors. Dr. Dekkers formerly served as the CEO of Bayer AG, and as the CEO of Thermo Fisher Scientific, Inc. At Bayer he oversaw one of the largest global animal health companies.
“Most current medicines in the $40B veterinary pharma market are derived from drugs that have been originally developed for humans. There is of course nothing wrong with that, but there are many animal-specific diseases that require a targeted effort. I like Animol Discovery’s approach to use its breakthrough drug discovery platform to specifically address significant unmet needs in animals. I am looking forward to working with the team to optimize the opportunity ahead,” said Dr. Dekkers.
“It is a great pleasure to be able to welcome Marijn Dekkers to our Board of Directors. Dr. Dekkers is an exceptional industry leader with a track record of turning innovation into successful businesses across the spectrum of life sciences, including in animal health,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “He is an excellent addition to our team of experienced industry leaders.”
“I am also delighted to bring Doug Hutchens on board as chief scientific officer. Dr. Hutchens brings a wealth of industry experience in animal health research and product development; having someone who has also served as Chief Veterinary Officer within a major animal health company brings huge value to our expanding team,” added Dr. Plant.
“I am thrilled by the prospect of joining Animol’s dynamic and experienced team as chief scientific officer,” said Doug Hutchens, DVM, PhD. “The company’s ability to interrogate protein targets with billions of DNA-tagged molecules and, using DNA sequencing, identify selective inhibitors from numerous diverse chemical families is game changing in animal health drug discovery. Leveraging these data with proprietary, highly predictive machine learning algorithms, is enabling the identification of novel drug-like compounds in a matter of weeks from the initial DEL screen. This technology platform greatly expands the opportunities, significantly increases the probability, and accelerates the timeline in developing new classes of therapeutic molecules.”
About Animol
Animol is a pioneer in using state of the art drug discovery technology to discover small molecule active pharmaceutical ingredients to transform standards of care in veterinary medicine. The company is reducing the time and cost to discover novel active ingredients utilizing DNA-encoded libraries, machine learning/AI and structure-based design.
Animol is a private company based in Boston, Massachusetts. For more information see www.Animol-discovery.com
About Novalis LifeSciences LLC
Novalis LifeSciences LLC is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. For more information, visit www.novalislifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005186/en/
Contact information
Dr. Andrew Plant
CEO
Animol Discovery, Inc.
andrew.plant@animol-discovery.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everyone Talks CX. Almost No One Delivers.7.7.2025 11:51:00 EEST | Press release
Global cloud communications platform Infobip has today released findings from a new study conducted by Harvard Business Review Analytic Services (HBR-AS) revealing a sharp disconnect in customer experience (CX): while 93% of those surveyed from the HBR audience recognize the high importance of creating positive conversational experiences, only 36% believe their organization is highly effective at it. Even more striking, just 11% report they’re highly effective using AI to deliver human-like conversations. The untapped potential of AI in customer engagement The report, “Conversational Experiences: The Untapped Potential of AI in Customer Engagement” highlights a gap between organizations’ ambitions and execution: while many use SMS, messaging apps, email and chatbots at key points, most still fail to deliver the seamless, intuitive conversations customers expect. “While everyone talks CX, almost no one delivers,” said Ben Lewis, VP Marketing and Growth at Infobip. “When brands can’t del
Geneva Business School Celebrates 30 Years of International Excellence at Its Graduation Ceremony in Barcelona7.7.2025 11:29:00 EEST | Press release
Geneva Business School held its traditional graduation ceremony this week in Barcelona, marked this year by a very special occasion: the institution’s 30th anniversary. With more than three decades of experience shaping business leaders in a globalized environment, Geneva Business School has consolidated its practical and international teaching model, inspired by Swiss academic standards, as a key reference in the Spanish educational ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250704769866/en/ “Our students are entering a world marked by complex geopolitical challenges, a world in urgent need of a new style of leadership. Their education at Geneva Business School has instilled in them a deep understanding of what it means to lead with integrity on a global stage,” said Mrs. Nicola Jackman, Global Head of Academics at Geneva Business School, during her speech at the ceremony. With campuses in Barcelona and Madri
IBA President Umar Kremlev Joins Terence Crawford and Tyson Fury to Usher in Golden Era of International Boxing Association7.7.2025 10:00:00 EEST | Press release
Some of boxing’s biggest names gathered in Istanbul as International Boxing Association (IBA) President Umar Kremlev unveiled plans for the sport’s “Golden Era.” Joined by pound-for-pound star Terence Crawford and heavyweight icon Tyson Fury, Kremlev outlined IBA’s vision to build an ecosystem supporting fighters at every level- amateur, professional, and bare-knuckle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707636910/en/ IBA Press Conference (Photo: AETOSWire) “I’m thrilled to welcome so many champions to this event for the development of boxing,” said Kremlev. “Our goal is to ensure every athlete knows IBA is their home. Wherever a boxer is, IBA will support them. It’s our duty to create opportunities for children to build better futures for themselves and their families.” Kremlev stressed boxing’s roots: “We’re creating an ecosystem covering amateur, professional, and bare-knuckle boxing. Why bare-knuckle? That’
Nrep and Slate Asset Management Enter Agreement on Essential Real Estate Portfolio in Denmark7.7.2025 09:00:00 EEST | Press release
Urban Partners’ real estate arm, Nrep, together with StepStone Real Estate (“SRE”), the real estate arm of private markets investment firm StepStone Group (Nasdaq: STEP), are pleased to announce the sale of a portfolio of five grocery-anchored retail properties and two adjacent residential properties in Greater Copenhagen. The portfolio is being acquired by a joint venture between Slate Asset Management (“Slate” or the “Firm”), a global investor and manager focused on essential real estate and infrastructure assets, and OneIM, a global alternative investment manager that invests across the capital structure in a range of asset classes. OneIM is Slate’s capital partner in the transaction, which is the first for Slate and OneIM’s joint venture. The joint venture is actively targeting further acquisitions across the European essential retail sector. The acquisition marks Slate’s first investment in Denmark and further increases the Firm’s portfolio of high-quality essential real estate as
SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release
SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom